Literature DB >> 16434784

Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children.

Milap C Nahata1, Richard S Morosco, Michael T Brady.   

Abstract

PURPOSE: The stability of sildenafil citrate 2.5 mg/mL in two extemporaneously prepared oral suspensions stored at 4 and 25 degrees C was studied.
METHODS: Thirty 25-mg tablets of sildenafil citrate were ground to powder, and the powder was combined with a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of methylcellulose 1% and Simple Syrup, NF, to produce two 2.5-mg/mL suspensions. Five plastic bottles of each suspension were stored in amber plastic prescription bottles at 4 or 25 degrees C. Samples were collected on days 0, 7, 14, 28, 42, 56, 70, and 91 for analysis of sildenafil content by high-performance liquid chromatography; pH was also measured. Samples were visually observed against black and white backgrounds.
RESULTS: The mean concentration of sildenafil citrate exceeded 98% of the initial concentration in all samples at both temperatures throughout the 91-day study period. No changes in pH, odor, or physical appearance were observed.
CONCLUSION: Sildenafil citrate 2.5 mg/mL in two extemporaneously compounded oral suspensions was stable for 91 days in plastic prescription bottles at 4 and 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434784     DOI: 10.2146/ajhp050208

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.

Authors:  Komathi Balakrishnan; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2006-07-26       Impact factor: 4.335

Review 2.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 3.  Sildenafil for the treatment of pulmonary hypertension in pediatric patients.

Authors:  Alice J Huddleston; Chad A Knoderer; Jennifer L Morris; Eric S Ebenroth
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

Review 4.  Drug Treatment of Pulmonary Hypertension in Children.

Authors:  Catherine M Avitabile; Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

5.  Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder.

Authors:  Abdel Naser Zaid; Mohyeddin Assali; Samah Zalmout; Aseel Basheer
Journal:  Eur J Hosp Pharm       Date:  2016-06-15

6.  Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension.

Authors:  Ryota Akabane; Touko Sato; Atsushi Sakatani; Mizuki Ogawa; Masayoshi Nagakawa; Hirosumi Miyakawa; Yuichi Miyagawa; Hiroyuki Tazaki; Naoyuki Takemura
Journal:  J Vet Med Sci       Date:  2020-02-26       Impact factor: 1.267

7.  Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports.

Authors:  Alexandra Carls; Julia Winter; Yeliz Enderle; Jürgen Burhenne; Matthias Gorenflo; Walter E Haefeli
Journal:  J Med Case Rep       Date:  2014-05-30

8.  Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.

Authors:  Attawadee Sae Yoon; Somchai Sawatdee; Chuthamas Woradechakul; Kridsada Sae Chee; Apichart Atipairin
Journal:  Sci Pharm       Date:  2015-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.